Certain male baldness pattern associated with increased risk of aggressive prostate cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Clinical Oncology, frontal plus moderate vertex baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
In the study, researchers analyzed data from 39,070 men who participated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. In order to be included, patients had to have no prior cancer diagnoses, excluding nonmelanoma skin cancer, and be able to recall their hair-loss patterns at age 45 using a modified Norwood-Hamiton scale.
The researchers identified 1,138 cases of prostate cancer, 571 of which were aggressive, during a median follow-up of 2.78 years. Patients with frontal plus moderate vertex baldness at age 45 was not significantly linked with overall prostate cancer risk or nonaggressive prostate cancer risk compared with men with no baldness. By contrast, the same type of baldness was significantly associated with a 40% increased risk for developing aggressive prostate cancer. Other types of baldness were not associated with an increased risk of prostate cancer.
Baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
Increasingly, evidence is suggesting that both prostate cancer and male pattern baldness are linked to increased levels of androgens (male sex hormones) and androgen receptors.
In 2013, Medical News Today reported on a study from researchers at the University of Pennsylvania in Philadelphia, who found that African-American men who experience baldness were 69% more likely to develop prostate cancer than those with no baldness.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|